{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:06:09Z","timestamp":1780625169062,"version":"3.54.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ejca.2021.07.033","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T12:49:44Z","timestamp":1629809384000},"page":"138-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)"],"prefix":"10.1016","volume":"156","author":[{"given":"Volker","family":"M\u00f6bus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"L\u00fcck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehart","family":"Ladda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Klare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1365-2414","authenticated-orcid":false,"given":"Marcus","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Maria","family":"Grischke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grischa","family":"Wachsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6602-7562","authenticated-orcid":false,"given":"Helmut","family":"Forstbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Untch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Marm\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Uwe","family":"Blohmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8537-3743","authenticated-orcid":false,"given":"Christian","family":"Jackisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Huober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9715-7260","authenticated-orcid":false,"given":"Elmar","family":"Stickeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1381-8595","authenticated-orcid":false,"given":"Mattea","family":"Reinisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno V.","family":"Sinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Janni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Denkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1693-8557","authenticated-orcid":false,"given":"Jenny","family":"Furlanetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Engels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Solbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Schmatloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Burchardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6488-4958","authenticated-orcid":false,"given":"Sibylle","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.07.033_bib1","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"Citron","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.07.033_bib2","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/S0140-6736(14)62048-1","article-title":"Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2x2 factorial, randomized phase 3 trial","volume":"385","author":"Del Mastro","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.07.033_bib3","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2008.20.3133","article-title":"Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer","volume":"27","author":"Untch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.07.033_bib4","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/annonc\/mdx690","article-title":"Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial","volume":"29","author":"M\u00f6bus","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.07.033_bib5","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2016.15865","article-title":"Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer: a randomized clinical trial","volume":"316","author":"Foukakis","year":"2016","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ejca.2021.07.033_bib6","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/S0140-6736(18)33137-4","article-title":"Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials","volume":"393","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.07.033_bib7","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1038\/sj.bjc.6601366","article-title":"Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer","volume":"89","author":"Cameron","year":"2003","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2021.07.033_bib8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/bjc.1997.49","article-title":"Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer","volume":"75","author":"Saarto","year":"1997","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2021.07.033_bib9","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1200\/JCO.2005.11.013","article-title":"Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer","volume":"23","author":"Ibrahim","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.07.033_bib10","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1200\/JCO.18.01842","article-title":"NAB-paclitaxel improves disease-free survival in early breast cancer: GBG 69-GeparSepto","volume":"37","author":"Untch","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.07.033_bib11","article-title":"Adjuvant phase III trial to compare intense dose-dense adjuvant treatment with EnPC to dose dense, tailored therapy with dtEC-dtD for patients with high-risk early breast cancer (GAIN-2)","volume":"31","author":"M\u00f6bus","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.07.033_bib12","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(02)08272-7","article-title":"Quantification of the completeness of follow-up","volume":"359","author":"Clark","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.07.033_bib13","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Pearson","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.ejca.2021.07.033_bib14","first-page":"7067","article-title":"A Gompertzian model of human breast cancer growth","volume":"48","author":"Norton","year":"1988","journal-title":"Canc Res"},{"key":"10.1016\/j.ejca.2021.07.033_bib15","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/jamaoncol.2019.6276","article-title":"High-dose chemotherapy with hematopoietic stem cell transplant in patients with high-risk breast cancer and 4 or more involved axillary lymph nodes. 20-Year follow-up of a phase 3 randomized clinical trial","volume":"6","author":"Steenbruggen","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.07.033_bib16","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1200\/JCO.2012.48.1275","article-title":"Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial","volume":"31","author":"Swain","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.07.033_bib17","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S1470-2045(17)30404-7","volume":"18","author":"Cameron","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.07.033_bib18","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/annonc\/mdx203","article-title":"German Adjuvant Intergroup Node-Positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients","volume":"28","author":"M\u00f6bus","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.07.033_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2009.22.1077","article-title":"Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer","volume":"28","author":"Burnell","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921004913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921004913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:33:22Z","timestamp":1760733202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921004913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":19,"alternative-id":["S0959804921004913"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.07.033","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.07.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}